Home Industry Bioprinting company mimiX biotherapeutics launches financing round

Bioprinting company mimiX biotherapeutics launches financing round

mimiX biotherapeutics, a Swiss medical device company specializing in life sciences with a 3D bioprinting platform that uses patented Sound Induced Morphogenesis (SIM). The company announced a funding round to accelerate the clinical implementation of its FastSkin technology.

FastSkin is an advanced dermal substitute for acute and chronic wound treatment. It creates new therapeutic opportunities in the treatment of complex wounds, a major social burden and clinical unmet need in skin cancer, acute and chronic wounds.

“FastSkin is a major advance in personalized regenerative medicine, opening the door to new treatment options while increasing patient accessibility” stated Marc Thurner, mimiX biotherapeutics Chairman and CEO.

The global skin cancer market is projected to reach USD 14.55bn by 2027. The increase in diabetes, obesity & chronic conditions is expected to augment the demand for advanced wound care products, a market estimated to USD 24bn by 2030.

The company is launching a funding round in January 2023 to accelerate U.S.market clearance and market launch.

Find out more about mimiX biotherapeutics at mimixbio.com.

Subscribe to our Newsletter

3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.

Privacy Policy*

You can find the privacy policy for the newsletter here. You can unsubscribe from the newsletter at any time. For further questions, you can contact us here.